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Insertion and mutation
Merkel cell polyomavirus (MCV) was recently identified as 
being integrated into the genome of Merkel cell carcinoma 
(MCC) tumors. Shuda and colleagues isolated MCV T-antigen 
oncoprotein sequences from tumor and nontumor sources to 
examine potential changes in these conserved genes. In all 
eight MCV-positive tumor samples, the large T (LT)-antigen 
protein was truncated in exon 2, which encodes the LT heli-
case; however, the LT-antigen Rb-binding domain, which has 
been shown to contribute to tumors in other animal polyo-
mavirus models, remained intact in these samples. In virus-
replication assays, tumor-derived MCV mutations prevented 
LT-dependent origin replication. Together, the occurrence 
of T-antigen mutations and virus monoclonal insertions in 
tumors suggests that MCV is not a passenger virus and sup-
ports the function of MCV in MCC tumorigenesis. In addi-
tion, the requirement for two mutagenic events—integration 
and LT truncation—underscores the rare occurrence of MCC 
tumors following a relatively common viral infection. (Proc 
Natl Acad Sci USA 105:16272–7, 2008)
All in the liposome
The thrombin receptor protease-activated receptor-1 (PAR-1) 
is overexpressed in highly metastatic melanoma cells. 
Because PAR-1 is upstream of genes involved in adhesion, 
invasion, and angiogenesis, this gene likely contributes to 
the metastatic process of human melanoma. Villares and 
colleagues silenced PAR-1 in vivo by incorporating siRNA 
for this gene into neutral liposomes, which have been shown 
to be a much safer route for targeting therapy than viral vec-
tors. These PAR-1 siRNA-containing liposomes significantly 
inhibited both melanoma tumor growth and lung metastasis 
in mice. In addition, invasion and angiogenesis factors were 
decreased in these mice following liposome delivery. These 
data indicate that PAR-1 is indeed a regulator of melanoma 
growth and metastasis. Delivery of melanoma treatment via 
liposomes is clearly feasible and effective, and the success 
of this technique will fuel exploration of therapy options for 
human melanoma. (Cancer Res 68:9078–86, 2008)
Tumor killers in the bone marrow
Adoptive transfer of dendritic cells (DCs) potentially inhibits 
tumor growth via stimulation of innate and adaptive immune 
responses. Although stimulation of adaptive immunity is 
achieved via ex vivo priming of DC followed by intratumoral 
injection, unpulsed DCs injected at sites distant to a tumor 
have also induced tumoricidal activity. Himoudi and col-
leagues demonstrated that unpulsed bone marrow–derived 
DCs administered subcutaneously were capable of inhib-
iting the growth of small, established tumors via a natural 
killer (NK) and T-cell-mediated immune response. Following 
isolation from the bulk bone marrow DC culture, interferon-
producing killer DCs (IKDCs) were shown to be necessary 
and sufficient for tumoricidal activity in mice. These IKDCs 
exhibited cytotoxic effects on cell lines in vitro, but in immu-
nodeficient mice lacking NK or T cells these cells had no 
effect on tumor growth, confirming the importance of host 
effector cells for tumor regression. Overall, IKDCs were 
remarkably efficient in inducing antitumor immunity in the 
mice and thus offer a variety of potential clinical applica-
tions. (J Immunol 181:6654–63, 2008)
Modeling lesion growth
Although expansion of premalignant lesions is clearly an 
important step in cancer progression, the mechanism of 
clonal expansion has not yet been fully confirmed. One pos-
sible mechanism for expansion involves the acquisition of a 
mutation to increase proliferation. Alternatively, colonization 
of adjacent space left vacant by neighboring cell death is a 
possibility. Chao and colleagues used computer simulation 
methods to explore clonal expansion in the spatially struc-
tured epithelium because conventional studies have associ-
ated lesion growth with elevated cell proliferation without 
regard to tissue architecture. The computer model took into 
account empirical lesion numbers and sizes that correspond-
ed to p53-mutant lesions observed in skin of mice exposed 
to UVB. According to these simulations, the observed growth 
of the epidermal precancerous lesions closely fits the frontier 
model, which asserts that agents such as radiation stimulate 
cell death along the frontier of the mutant clone, allowing 
expansion into this cellular void. (Proc Natl Acad Sci USA 
105:15034–9, 2008)
Transplant to improve neuropathy
Polyneuropathy, organomegaly, endocrinopathy, M-protein, 
and skin changes (POEMS) syndrome causes demyelinating-
axonal mixed neuropathy with multiorgan involvement 
and plasma cell dyscrasia. Recently, high-dose melphalan 
chemotherapy in conjunction with autologous peripheral 
blood stem cell transplantation (auto-PBSCT) was shown to 
be useful in treating this disease. Kuwabara and colleagues 
investigated the extent and time course of the neurological 
improvement in nine patients following auto-PBSCT. The use 
of neurologic disability scaling, nerve conduction studies, 
and measurement of serum vascular endothelial growth 
factor levels revealed substantial neurologic recovery and 
improved quality of life in all patients. Although transplant-
related death has been estimated at approximately 5%, 
auto-PBSCT may be considered a first-line treatment for 
POEMS patients based on the dramatic improvement in 
debilitating neuropathy. (Neurology 71:1691–5, 2008)
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